Strategic acquisition Eurofins CALIXAR was acquired by Eurofins Discovery in 2023, presenting an opportunity to align with a larger drug discovery ecosystem, leverage expanded customer access, and cross-sell membrane protein isolation capabilities to Eurofins’ global client base.

High value target platform Specialization in native and functional full-length membrane proteins for targets like GPCRs and ion channels positions CALIXAR as a critical supplier for Structure Based Drug Design and High Throughput Screening workflows, ideal for pharmaceutical companies seeking high-purity targets.

Flexible engagement CALIXAR offers multiple commercial models including fee-for-service, risk sharing, exclusivity, and licensing, enabling sales teams to tailor engagements for biotech startups, academic collaborations, or pharma partnerships at various risk tolerances.

Global distribution network Past distribution partnerships across multiple regions (Europe, Asia, North America) and distributors like Clinisciences, BioD, and Scientist.com indicate readiness and precedent for channel sales, co-marketing, and marketplace storefronts to expand reach.

Proof of impact Publications and collaborations (Cell Reports, Janssen) coupled with a documented move to Eurofins’ platform suggest credibility and validation of technology, which can be leveraged in pitch materials to de-risk conversations with potential customers.